<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAU</journal-id>
<journal-id journal-id-type="hwp">sptau</journal-id>
<journal-title>Therapeutic Advances in Urology</journal-title>
<issn pub-type="ppub">1756-2872</issn>
<issn pub-type="epub">1756-2880</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1756287212459549</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756287212459549</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Experience with imidafenacin in the management of overactive bladder disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Takeuchi</surname><given-names>Takumi</given-names></name>
<aff id="aff1-1756287212459549">Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Zaitsu</surname><given-names>Masayoshi</given-names></name>
<aff id="aff2-1756287212459549">Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Mikami</surname><given-names>Koji</given-names></name>
<aff id="aff3-1756287212459549">Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1756287212459549"><email>takeuchit@abelia.ocn.ne.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>58</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Overactive bladder (OAB) is a chronic syndrome defined by symptoms of urinary urgency with no underlying medical causes. First-line treatment of OAB comprises fluid intake advice and bladder training, supplemented by anticholinergic drugs if necessary. Owing to the chronic nature of OAB, the ideal anticholinergic treatment should have good long-term efficacy and tolerability. There are many anticholinergics available, although some of these are not specific for the bladder and can cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment. Imidafenacin (a newer anticholinergic which has been marketed in Japan since 2007) was developed to improve the tolerability of anticholinergic therapy. This article summarizes the pharmacological properties, pharmacokinetics, clinical efficacy and tolerability of imidafenacin in the treatment of OAB. Data from key clinical studies of imidafenacin show that it has a fast onset of action and is effective for the treatment of OAB. It selectively binds to muscarinic receptors in the bladder and is associated with a good safety profile compared with other anticholinergics. The clinical efficacy, superior tolerability and adjustable dosing of imidafenacin make it a good anticholinergic for the treatment of OAB.</p>
</abstract>
<kwd-group>
<kwd>bladder selectivity</kwd>
<kwd>efficacy</kwd>
<kwd>imidafenacin</kwd>
<kwd>overactive bladder</kwd>
<kwd>pharmacokinetics</kwd>
<kwd>tolerability</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1756287212459549" sec-type="intro">
<title>Introduction</title>
<p>Overactive bladder (OAB) is a chronic syndrome defined by symptoms of urinary urgency with no underlying medical causes [<xref ref-type="bibr" rid="bibr2-1756287212459549">Abrams <italic>et al</italic>. 2002</xref>]. The most prevalent symptom is urinary urgency which is generally accompanied by urinary frequency and nocturia, or urgency incontinence [<xref ref-type="bibr" rid="bibr2-1756287212459549">Abrams <italic>et al</italic>. 2002</xref>]. OAB is a common disease with an overall prevalence of at least 16% in adults in the USA and Europe [<xref ref-type="bibr" rid="bibr27-1756287212459549">Milsom <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr42-1756287212459549">Stewart <italic>et al</italic>. 2003</xref>]. In Japan, the incidence of OAB in men and women aged at least 40 years is 12.4% [<xref ref-type="bibr" rid="bibr13-1756287212459549">Homma <italic>et al</italic>. 2005</xref>]. Furthermore, OAB is strongly correlated with age; for example, the incidence of OAB in older people (≥70 years old) in Japan exceeds 30% [<xref ref-type="bibr" rid="bibr13-1756287212459549">Homma <italic>et al</italic>. 2005</xref>]. OAB is associated with a reduced quality of life and influences the social, psychological, occupational, daily living, physical and sexual aspects of a patient’s life [<xref ref-type="bibr" rid="bibr3-1756287212459549">Abrams <italic>et al</italic>. 2000</xref>].</p>
<p>First-line treatment of OAB comprises fluid intake advice and bladder training, supplemented by anticholinergic drugs if necessary. As OAB is a chronic disease, anticholinergics should be chosen based on long-term efficacy and safety. There are a variety of anticholinergic drugs available in Japan for the treatment of OAB: solifenacin succinate, tolterodine tartrate, propiverine, oxybutynin chloride and imidafenacin (<xref ref-type="table" rid="table1-1756287212459549">Table 1</xref>). While these all act on muscarinic receptors, they have different tolerability profiles. Those which are not specific for the bladder cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment [<xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. In comparison, imidafenacin (a newer anticholinergic which has been marketed in Japan since 2007) was developed to improve the tolerability of anticholinergic therapy by being specific for the M3 receptor subtype which is found mainly in the bladder [<xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. This article provides an overview of the pharmacokinetics, pharmacological properties, clinical efficacy and tolerability of imidafenacin in the treatment of OAB, including our experience in the LIST study.</p>
<table-wrap id="table1-1756287212459549" position="float">
<label>Table 1.</label>
<caption>
<p>Anticholinergic drugs available in the Japanese market for the treatment of overactive bladder.</p>
</caption>
<graphic alternate-form-of="table1-1756287212459549" xlink:href="10.1177_1756287212459549-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Drug</th>
<th align="left">Imidafenacin</th>
<th align="left">Solifenacin succinate</th>
<th align="left">Tolterodine tartrate</th>
<th align="left">Propiverine</th>
<th align="left">Oxybutynin chloride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval date in Japan</td>
<td>2007</td>
<td>2006</td>
<td>2006</td>
<td>1993</td>
<td>1988</td>
</tr>
<tr>
<td colspan="6">Dosage and administration</td>
</tr>
<tr>
<td> Formulation</td>
<td>Tablet</td>
<td>Tablet</td>
<td>Capsule</td>
<td>Tablet</td>
<td>Tablet</td>
</tr>
<tr>
<td/>
<td>Orally disintegrating</td>
<td>Orally disintegrating</td>
<td/>
<td>Granule</td>
<td/>
</tr>
<tr>
<td> Recommended dosing</td>
<td>0.1 mg twice a day</td>
<td>5 mg once a day</td>
<td>4 mg once a day</td>
<td>20 mg once a day</td>
<td>2–3 mg three times a day</td>
</tr>
<tr>
<td/>
<td>0.2 mg twice a day</td>
<td>10 mg once a day</td>
<td/>
<td>20 mg twice a day</td>
<td/>
</tr>
<tr>
<td> Dose adjustments</td>
<td>None</td>
<td>Hepatic impairment</td>
<td>Hepatic impairment</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td/>
<td/>
<td>Renal impairment</td>
<td>Renal impairment</td>
<td/>
<td/>
</tr>
<tr>
<td colspan="6">Pharmacokinetics</td>
</tr>
<tr>
<td> Half-life (h)</td>
<td>2.9</td>
<td>38</td>
<td>11.3</td>
<td>14.8</td>
<td>0.9</td>
</tr>
<tr>
<td> Elimination in urine (%)</td>
<td>65.6</td>
<td>69.2</td>
<td>77</td>
<td>16</td>
<td>22.2</td>
</tr>
<tr>
<td> % of unaltered drug eliminated in urine</td>
<td>9.4</td>
<td>14.7</td>
<td>&lt;1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td colspan="6">Pharmacodynamics</td>
</tr>
<tr>
<td> Metabolic enzyme</td>
<td>CYP3A4/UGT1A2</td>
<td>CYP3A4/CYP2C19</td>
<td>CYP3A4/CYP2D6</td>
<td>CYP3A4</td>
<td>–</td>
</tr>
<tr>
<td> Pharmacological activity of the metabolite</td>
<td>None</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td> Anticholinergic effect</td>
<td>M3≥M1&gt;M2</td>
<td>M3&gt;M1&gt;M2</td>
<td>No selectivity</td>
<td>No selectivity (calcium antagonistic effect)</td>
<td>No selectivity (smooth muscle relaxant)</td>
</tr>
<tr>
<td colspan="6">Muscarinic selectivity [<xref ref-type="bibr" rid="bibr21-1756287212459549">Kobayashi <italic>et al</italic>. 2007b</xref>; <xref ref-type="bibr" rid="bibr30-1756287212459549">Ohtake <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr49-1756287212459549">Yamazaki <italic>et al</italic>. 2011</xref>]</td>
</tr>
<tr>
<td> Efficacy ratio of salivary:bladder binding</td>
<td>X8.8</td>
<td>–</td>
<td>X5.0</td>
<td>X0.9</td>
<td>X1.9</td>
</tr>
<tr>
<td> </td>
<td>–</td>
<td>X6.5</td>
<td>X2.4</td>
<td>X1.1</td>
<td>–</td>
</tr>
<tr>
<td> </td>
<td>X15</td>
<td>X1.7</td>
<td>X2.5</td>
<td>X1.1</td>
<td>–</td>
</tr>
<tr>
<td colspan="6">Receptor binding duration (h)</td>
</tr>
<tr>
<td> Citation</td>
<td><xref ref-type="bibr" rid="bibr47-1756287212459549">Yamada <italic>et al</italic>. [2011b</xref>]</td>
<td><xref ref-type="bibr" rid="bibr32-1756287212459549">Oki <italic>et al</italic>. [2005]</xref></td>
<td><xref ref-type="bibr" rid="bibr31-1756287212459549">Oki <italic>et al</italic>. [2006]</xref></td>
<td><xref ref-type="bibr" rid="bibr15-1756287212459549">Ito <italic>et al</italic>. [2010]</xref></td>
<td><xref ref-type="bibr" rid="bibr25-1756287212459549">Maruyama <italic>et al</italic>. [2008]</xref></td>
</tr>
<tr>
<td> Bladder</td>
<td>3–6</td>
<td>1–6</td>
<td>6–12</td>
<td>3–6</td>
<td>2</td>
</tr>
<tr>
<td> Salivary glands</td>
<td>1–3</td>
<td>1–6</td>
<td>–</td>
<td>3</td>
<td>0.5–2</td>
</tr>
<tr>
<td> Colon</td>
<td>–</td>
<td>1–12</td>
<td>–</td>
<td>3–6</td>
<td>0.5–6</td>
</tr>
<tr>
<td colspan="6">Phase III trials</td>
</tr>
<tr>
<td> Citations</td>
<td><xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi [2009]</xref></td>
<td><xref ref-type="bibr" rid="bibr5-1756287212459549">Cardozo <italic>et al</italic>. [2006]</xref>; <xref ref-type="bibr" rid="bibr6-1756287212459549">Chapple <italic>et al</italic>. [2006]</xref>; <xref ref-type="bibr" rid="bibr41-1756287212459549">Staskin and Te [2006]</xref></td>
<td><xref ref-type="bibr" rid="bibr10-1756287212459549">Homma <italic>et al</italic>. [2003]</xref></td>
<td><xref ref-type="bibr" rid="bibr50-1756287212459549">Yoshida <italic>et al</italic>. [2010]</xref></td>
<td><xref ref-type="bibr" rid="bibr22-1756287212459549">Koyanagi <italic>et al</italic>. [1986]</xref></td>
</tr>
<tr>
<td> Control arm</td>
<td>Propiverine</td>
<td>Propiverine</td>
<td>Oxybutynin chloride</td>
<td>Placebo</td>
<td>Placebo</td>
</tr>
<tr>
<td> Treatment period</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>2 weeks</td>
<td>2 weeks</td>
</tr>
<tr>
<td> Adverse events (%)</td>
<td>45.5</td>
<td>45.5</td>
<td>54.6</td>
<td>20.9</td>
<td>13.9</td>
</tr>
<tr>
<td colspan="6">Long-term (52-week) trial</td>
</tr>
<tr>
<td> Citations</td>
<td><xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi [2008]</xref></td>
<td><xref ref-type="bibr" rid="bibr5-1756287212459549">Cardozo <italic>et al</italic>. [2006]</xref>; <xref ref-type="bibr" rid="bibr6-1756287212459549">Chapple <italic>et al</italic>. [2006]</xref>; <xref ref-type="bibr" rid="bibr41-1756287212459549">Staskin and Te [2006]</xref></td>
<td><xref ref-type="bibr" rid="bibr44-1756287212459549">Takei and Homa [2005]</xref></td>
<td><xref ref-type="bibr" rid="bibr50-1756287212459549">Yoshida <italic>et al</italic>. [2010]</xref></td>
<td>–</td>
</tr>
<tr>
<td> Adverse events (%)</td>
<td>46.7</td>
<td>5 mg 58.8</td>
<td>54.3</td>
<td>18.0</td>
<td>–</td>
</tr>
<tr>
<td/>
<td/>
<td>10 mg 64.6</td>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section2-1756287212459549">
<title>Pharmacokinetics</title>
<p>Details of the key phase I trials of imidafenacin are summarized in <xref ref-type="table" rid="table2-1756287212459549">Table 2</xref>.</p>
<table-wrap id="table2-1756287212459549" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of the pharmacokinetics of imidafenacin.</p>
</caption>
<graphic alternate-form-of="table2-1756287212459549" xlink:href="10.1177_1756287212459549-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Study design, patient population and characteristics (<italic>n</italic>)</th>
<th align="left" colspan="2">Dosage of imidafenacin</th>
<th align="left">Treatment duration</th>
<th align="left" colspan="2">Pharmacokinetics</th>
<th align="left">Safety summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single dose study [<xref ref-type="bibr" rid="bibr38-1756287212459549">Shimada <italic>et al.</italic> 2007d</xref>]</td>
<td>Phase I safety and PK in healthy adult male volunteers (32)</td>
<td colspan="2">0.025 mg oral<break/> 0.05 mg oral<break/> 0.1 mg oral<break/> 0.25 mg oral<break/> 0.5 mg oral</td>
<td>Single dose</td>
<td colspan="2">Unchanged drug:<break/> <italic>C</italic><sub>max</sub> 109, 180, 382, 1010 and 1940 pg/ml<break/> T<sub>max</sub> (median) 1.5–1.8 h<break/> <italic>t</italic><sub>½</sub> 2.6–3.0 h<break/> Urinary excretion 5.5–8.6%<break/> Time to urinary excretion &lt;24 h <break/>M-2 metabolite:<break/> <italic>C</italic><sub>max</sub> 26, 51, 110, 293 and 445 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 1.5–2.0 h<break/> <italic>t</italic><sub>½</sub> 2.6–3.3 h<xref ref-type="table-fn" rid="table-fn1-1756287212459549">*</xref><break/> Urinary excretion 5.9–7.1%<break/> Time to urinary excretion &lt;24 h</td>
<td>AEs<break/> Ventricular extrasystoles: short run in 1 subject (0.05 mg); single occurrence in 2 subjects (0.5 mg)<break/> Supraventricular extrasystoles: single occurrence in 1 subject (0.5 mg)<break/> Electrocardiogram ambulatory abnormal: single occurrence in 3 subjects (0.1 mg)<break/> Dry mouth: 1 subject (0.25 mg), 3 subjects (0.5 mg)<break/> Asthenopia (tired eyes): 1 subject (0.5 mg)<break/> White blood cells urine positive: 1 subject (0.1 mg), 1 subject (0.5 mg)</td>
</tr>
<tr>
<td>Repeated dose study [<xref ref-type="bibr" rid="bibr36-1756287212459549">Shimada <italic>et al.</italic> 2007b</xref>]</td>
<td>Phase I safety and PK in healthy adult male volunteers (6)</td>
<td colspan="2">0.25 mg oral twice a day</td>
<td>5 days</td>
<td>Unchanged drug:<break/>Single dose<break/> <italic>C</italic><sub>max</sub> 1240 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 1.0 h<break/> <italic>t</italic><sub>½</sub> 2.8 h<break/> AUC<sub>0–12</sub> 5580 pg.h/ml<break/> AUC<sub>0–∞</sub> 5970 pg.h/ml<break/> CL/F 42.3 liters/h<break/> Vd/F 202 liters<break/>M-2 metabolite:<break/> Single dose<break/> <italic>C</italic><sub>max</sub> 175 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 3.0 h<break/> <italic>t</italic><sub>½</sub> 3.5 h<break/> AUC<sub>0-12</sub> 1100 pg.h/ml<break/> AUC<sub>0–∞</sub> 1280 pg.h/ml</td>
<td>Day 5<break/> <italic>C</italic><sub>max</sub> 1240 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 2.0 h<break/> <italic>t</italic><sub>½</sub> 2.7 h<break/>Day 5<break/> <italic>C</italic><sub>max</sub> 189 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 4.0 h<break/> <italic>t</italic><sub>½</sub> 4.0 h<break/> AUC<sub>0–12</sub> 1290 pg.h/ml<break/> AUC<sub>0–∞</sub> 1520 pg.h/ml</td>
<td>AEs:<break/> Dry mouth: 1 subject<break/> Increased AST and ALT: 1 subject</td>
</tr>
<tr>
<td>Food-effect study [<xref ref-type="bibr" rid="bibr34-1756287212459549">Shimada <italic>et al.</italic> 2007a</xref>]</td>
<td colspan="2">Phase I fasted and fed PK in healthy adult male Japanese volunteers (12)</td>
<td>0.1 mg oral</td>
<td>Single dose</td>
<td>Fasted state<break/>Unchanged drug<break/> <italic>C</italic><sub>max</sub> 471 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 1.5 h<break/> <italic>t</italic><sub>½</sub> 2.9 h<break/> AUC<sub>0–∞</sub> 2400 pg.h/ml<break/> Urinary recovery 7.3%<break/>Fed state:<break/> C<sub>max</sub> 611 pg/ml<break/> T<sub>max</sub> (median) no difference <italic>versus</italic> fasted state<break/> AUC<sub>0-∞</sub> slight increase <italic>versus</italic> fasted state<break/> Urinary recovery 31.0%</td>
<td>M-2 metabolite<break/> <italic>C</italic><sub>max</sub> 97.9 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 2.0 h<break/> Urinary recovery 4.4%</td>
<td>AEs<break/> Constipation: mild constipation reported in 1 subject in the fasted state<break/> Dry mouth: mild dry mouth reported in 1 subject in the fed state</td>
</tr>
<tr>
<td>Older subjects [<xref ref-type="bibr" rid="bibr37-1756287212459549">Shimada <italic>et al.</italic> 2007c</xref>]</td>
<td colspan="2">Phase I safety and PK in elderly (≥65 yrs) male and female subjects (9)</td>
<td>0.1 mg oral</td>
<td>Single dose</td>
<td colspan="2">Unchanged drug:<break/> <italic>C</italic><sub>max</sub> 445 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 1.0 h<break/> <italic>t</italic><sub>½</sub> 3.1 h<break/> Urinary excretion 4.9%<break/>M-2 metabolite:<break/> <italic>C</italic><sub>max</sub> 159 pg/ml<break/> <italic>T</italic><sub>max</sub> (median) 2.0 h<break/> <italic>t</italic><sub>½</sub> 3.6 h<break/> Urinary excretion 6.6%</td>
<td>AEs<break/> No adverse events or changes in laboratory values were reported</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1756287212459549">
<label>*</label>
<p>Doses of 0.1, 0.25 and 0.5 mg only</p>
</fn>
<fn id="table-fn2-1756287212459549">
<p>AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; AUC<sub>0–12</sub>, area under the plasma concentration-time curved from time 0 to 12 h; AUC<sub>0–∞</sub>, area under the plasma concentration-time curved from time 0 to infinity; CL/F, apparent total clearance; <italic>C</italic><sub>max</sub>, peak plasma concentration; PK, pharmacokinetic; <italic>t</italic><sub>½</sub>, half-life; <italic>T</italic><sub>max</sub>, time to peak plasma concentration; Vd/F, apparent volume of distribution.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Imidafenacin has a short half-life and undergoes urinary excretion within 24 h of administration (with the exception of its M-4 metabolite which is excreted within 48 h) [<xref ref-type="bibr" rid="bibr38-1756287212459549">Shimada <italic>et al</italic>. 2007d</xref>]. Plasma half-life values for single oral doses of imidafenacin 0.025, 0.05, 0.1, 0.25 or 0.5 mg in healthy volunteers were 2.6–3.0 h [<xref ref-type="bibr" rid="bibr38-1756287212459549">Shimada <italic>et al</italic>. 2007d</xref>]. Although it has been suggested that a short half-life could contribute to an unacceptable tolerability profile, this was not the case with imidafenacin. In this single-dose pharmacokinetic trial imidafenacin had an acceptable tolerability profile [<xref ref-type="bibr" rid="bibr38-1756287212459549">Shimada <italic>et al</italic>. 2007d</xref>].</p>
<p>After repeated doses of imidafenacin there was no drug accumulation in healthy volunteers [<xref ref-type="bibr" rid="bibr36-1756287212459549">Shimada <italic>et al</italic>. 2007b</xref>]. Oral imidafenacin 0.25 mg twice daily for 5 days had a peak plasma concentration (<italic>C</italic>
<sub>max</sub>) and pharmacokinetic parameters comparable to those after the initial dose [<xref ref-type="bibr" rid="bibr36-1756287212459549">Shimada <italic>et al</italic>. 2007b</xref>]. This lack of accumulation means that adverse events can be easily managed. In case of urinary retention, symptoms are easily reduced by stopping treatment. In contrast, urinary retention symptoms induced by other anticholinergic treatments with a long half-life (such as solifenacin) can persist after treatment cessation [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>].</p>
<p>The pharmacokinetics of imidafenacin are not greatly influenced by food or age. In the fed <italic>versus</italic> fasted state, the area under the plasma concentration–time curve from time 0 to 12 h (AUC<sub>0–12</sub>) and <italic>C</italic>
<sub>max</sub> increased by about 1.3 and 1.2 times, respectively [<xref ref-type="bibr" rid="bibr34-1756287212459549">Shimada <italic>et al</italic>. 2007a</xref>]. A single oral dose of imidafenacin 0.1 mg in healthy older men showed that the <italic>C</italic>
<sub>max</sub> of imidafenacin was about 1.2 times higher than that in younger patients (determined in an earlier study) [<xref ref-type="bibr" rid="bibr38-1756287212459549">Shimada <italic>et al</italic>. 2007d</xref>], while the AUC from time 0 to infinity (AUC<sub>0–∞</sub>) was similar between patient groups [<xref ref-type="bibr" rid="bibr37-1756287212459549">Shimada <italic>et al</italic>. 2007c</xref>]. Data suggest that there is no need to adjust the imidafenacin dose in patients with lowered metabolic function; whether it is due to age, sex or metabolic enzyme genotype [<xref ref-type="bibr" rid="bibr37-1756287212459549">Shimada <italic>et al</italic>. 2007c</xref>].</p>
<p>Finally, the metabolites of imidafenacin have no pharmacological activity [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>]. A preclinical study showed that, while imidafenacin has a high affinity for the muscarinic acetylcholine receptor subtypes, its metabolites (M-2, M-4 and M-9) had low affinity for these receptor subtypes [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>].</p>
</sec>
<sec id="section3-1756287212459549">
<title>Imidafenacin selectivity</title>
<p>Involuntary contractions of the detrusor muscle, the smooth muscle wall of the bladder, via the action of acetylcholine at the muscarinic receptor (in particular at the M2 and M3 receptor subtypes) is presumed to be the main cause of OAB [<xref ref-type="bibr" rid="bibr45-1756287212459549">Wein, 2001</xref>; <xref ref-type="bibr" rid="bibr7-1756287212459549">Chapple <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. The M2 receptor is the main cholinergic receptor in the urinary bladder; however, its function is not well defined [<xref ref-type="bibr" rid="bibr45-1756287212459549">Wein, 2001</xref>; <xref ref-type="bibr" rid="bibr7-1756287212459549">Chapple <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. Conversely, the M3 receptor is known to be directly involved with detrusor muscle contraction [<xref ref-type="bibr" rid="bibr45-1756287212459549">Wein, 2001</xref>; <xref ref-type="bibr" rid="bibr7-1756287212459549">Chapple <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. Muscarinic receptors also mediate gastrointestinal motility (M3), salivary gland function (M1, M3), heart rate and cardiac output (M2), cognitive processing (M1) and contraction of the ciliary muscle in the eye (M3) [<xref ref-type="bibr" rid="bibr9-1756287212459549">Herbison <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>].</p>
<p>Anticholinergics available for the treatment of OAB can either be nonselective or selective for one or more muscarinic receptor subtype (<xref ref-type="table" rid="table1-1756287212459549">Table 1</xref>). This selectivity affects each drug’s tolerability profile because anticholinergic drugs that are not specific for the bladder can cause adverse effects such as dry mouth, constipation, blurred vision or cognitive impairment [<xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>].</p>
<sec id="section4-1756287212459549">
<title>Bladder</title>
<p>Imidafenacin is the most bladder-selective anticholinergic available: it antagonizes both the M3 and M1 receptor subtypes <italic>in vitro</italic> and <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>, <xref ref-type="bibr" rid="bibr21-1756287212459549">2007b</xref>; <xref ref-type="bibr" rid="bibr47-1756287212459549">Yamada <italic>et al</italic>. 2011b</xref>]. Furthermore, preclinical research indicates that the duration of receptor binding of imidafenacin is longer in the bladder than in the salivary glands, heart, colon and brain [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>, <xref ref-type="bibr" rid="bibr21-1756287212459549">2007b</xref>; <xref ref-type="bibr" rid="bibr47-1756287212459549">Yamada <italic>et al</italic>. 2011b</xref>].</p>
</sec>
<sec id="section5-1756287212459549">
<title>Brain</title>
<p>Imidafenacin does not bind to muscarinic receptors in the brain. After intravenous administration in rats, neither imidafenacin nor darifenacin showed significant binding to muscarinic receptors in the brain whereas an injection of oxybutynin was associated with brain muscarinic receptor binding [<xref ref-type="bibr" rid="bibr50-1756287212459549">Yoshida <italic>et al</italic>. 2010</xref>]. In contrast to oxybutynin, imidafenacin also did not reduce cognitive function in a Morris water maze task in rats [<xref ref-type="bibr" rid="bibr21-1756287212459549">Kobayashi <italic>et al</italic>. 2007b</xref>].</p>
<p>Similar findings have been reported in clinical studies. In patients with OAB due to neurological diseases, imidafenacin increased bladder volume at first sensation together with increasing oxyhemoglobin concentration in the frontal micturition area, with no cognitive decline [<xref ref-type="bibr" rid="bibr33-1756287212459549">Sakakibara <italic>et al</italic>. 2011</xref>]. Furthermore, imidafenacin has been used effectively and safely for the treatment of OAB in patients with chronic stroke indicating that imidafenacin is associated with a good safety profile in neurological disorders [<xref ref-type="bibr" rid="bibr17-1756287212459549">Kaneko <italic>et al</italic>. 2011</xref>].</p>
<p>Finally, while cognitive adverse events with the anticholinergic tolterodine are rare because it has limited entry into the brain, some cases of central nervous system adverse events have been reported [<xref ref-type="bibr" rid="bibr8-1756287212459549">Diefenbach <italic>et al</italic>. 2008</xref>]. A retrospective analysis showed that these central nervous system adverse events are associated with mutations on one or both cytochrome P450 2D6 (CYP2D6) alleles [<xref ref-type="bibr" rid="bibr8-1756287212459549">Diefenbach <italic>et al</italic>. 2008</xref>]. Unlike tolterodine, imidafenacin is not metabolized by CYP2D6 [<xref ref-type="bibr" rid="bibr16-1756287212459549">Kanayama <italic>et al</italic>. 2007</xref>], so central nervous system adverse events are not expected.</p>
</sec>
<sec id="section6-1756287212459549">
<title>Heart</title>
<p>Normally, the muscarinic M2 receptor subtype mediates a decrease in heart rate, which is associated with bradycardia and decreased cardiac output [<xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>]. Therefore, antagonism of M2 receptors may lead to an increase in heart rate [<xref ref-type="bibr" rid="bibr4-1756287212459549">Andersson, 2004</xref>], as seen for propiverine, an anticholinergic which nonselectively inhibits M2 [<xref ref-type="bibr" rid="bibr1-1756287212459549">Abrams <italic>et al</italic>. 2006</xref>]. In comparison, imidafenacin does not appear to have any effect on the heart.</p>
<p>In a phase III, randomized controlled trial investigating the efficacy and tolerability of imidafenacin 0.1 mg twice daily and propiverine 20 mg/day in patients with OAB, there was no significant change from baseline in the QTc interval in imidafenacin recipients (–1.37 ± 21.53 ms), whereas propiverine was associated with a significant increase in the QTc interval (+7.56 ± 20.08 ms; <italic>p</italic> &lt; 0.0001) [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]. Furthermore, imidafenacin was not associated with a significant change from baseline in heart rate; whereas heart rate significantly (<italic>p</italic> &lt; 0.0001) increased in patients receiving propiverine (–0.8 ± 9.6 beats per minute [bpm] <italic>versus</italic> +4.4 ± 9.2 bpm) [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>].</p>
</sec>
<sec id="section7-1756287212459549">
<title>Salivary</title>
<p>Imidafenacin is a potent inhibitor of salivary secretion. A preclinical study showed that imidafenacin was associated with a strong inhibition of the acetylcholine-induced K<sup>+</sup> efflux from the salivary gland: only darifenacin was associated with more effective inhibition (darifenacin &gt; imidafenacin &gt; oxybutynin ≥ tolterodine &gt; pirenzepine ≥ propiverine &gt; methoctramine) [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>]. Furthermore, imidafenacin potently and dose-dependently inhibited carbamylcholine-stimulated salivary secretion in rats [<xref ref-type="bibr" rid="bibr21-1756287212459549">Kobayashi <italic>et al</italic>. 2007b</xref>]. Again, only darifenacin was associated with more effective inhibition [<xref ref-type="bibr" rid="bibr21-1756287212459549">Kobayashi <italic>et al</italic>. 2007b</xref>]. However, this study also indicated that, while imidafenacin potently inhibits salivary secretion, it has an 8.8-fold preference for the muscarinic receptors in the bladder responsible for distention-induced rhythmic bladder contraction (desired effect) over the muscarinic receptors responsible for salivary secretion (associated with dry mouth).</p>
<p>The selectivity of imidafenacin for the salivary gland was demonstrated in humans in a study conducted in 18 medical centers in Tokyo. This study showed that while imidafenacin was associated with the shortest amount of time to the development of dry mouth, it was associated with the fastest resolution of dry mouth symptoms 1 month after drug administration, compared with solifenacin, tolterodine or propiverine [<xref ref-type="bibr" rid="bibr18-1756287212459549">Kase <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section8-1756287212459549">
<title>Colon</title>
<p>The standard dose of imidafenacin (0.1 mg twice daily) shows little to no binding to muscarinic receptors in the colon whereas higher doses of imidafenacin have a short duration of binding to the colon [<xref ref-type="bibr" rid="bibr46-1756287212459549">Yamada <italic>et al</italic>. 2011a</xref>]. In comparison, while low-dose tolterodine does not bind to muscarinic receptors in the colon, high-dose tolterodine is associated with a long duration of binding to these muscarinic receptors [<xref ref-type="bibr" rid="bibr46-1756287212459549">Yamada <italic>et al</italic>. 2011a</xref>]. Tolterodine is generally well tolerated with low rates of constipation reported [<xref ref-type="bibr" rid="bibr44-1756287212459549">Takei and Homma, 2005</xref>]; however, in patients who are low metabolizers, the long duration of binding in the colon may lead to significant gastrointestinal adverse events.</p>
<p>Imidafenacin has a short half-life and has a short duration of muscarinic receptor binding, which leads to a period of time between imidafenacin administrations (a ‘resting phase’) when the drug has no antimuscarinic action in the colon. In comparison, anticholinergics with a long duration of muscarinic receptor binding, like solifenacin or propiverine, have no such ‘resting phase’. Furthermore, solifenacin is associated with a long duration of binding to the colon and propiverine has been shown to bind to muscarinic receptors in the colon longer than in the bladder which increases the risk of these drugs, inducing constipation [<xref ref-type="bibr" rid="bibr46-1756287212459549">Yamada <italic>et al</italic>. 2011a</xref>].</p>
<p>The timing of constipation also differs among anticholinergics. Time-dependent differences in the severity and incidence of adverse events between imidafenacin and solifenacin were observed in the LIST study (see efficacy and tolerability section for trial details) [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. While there was no difference in the incidence of constipation between imidafenacin and solifenacin in patients who received treatment for at least 12 weeks (log rank test: <italic>p</italic> = 0.0621) (data on file), the incidence of constipation over the long term (52 weeks) was significantly higher in solifenacin recipients (log rank test: <italic>p</italic> = 0.0017) [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>].</p>
<p>Meek and colleagues conducted a meta-analysis investigating the relationship between anticholinergics used for the treatment of OAB and constipation [<xref ref-type="bibr" rid="bibr26-1756287212459549">Meek <italic>et al</italic>. 2011</xref>]. They reported that the risk of constipation differed among drugs, and this variation may depend on differences in affinity for muscarinic receptors [<xref ref-type="bibr" rid="bibr26-1756287212459549">Meek <italic>et al</italic>. 2011</xref>]. Of the anticholinergics analyzed (darifenacin, fesoterodine, oxybutynin, trospium, solifenacin and tolterodine), solifenacin was associated with the highest risk of constipation [odds ratio (OR) compared with placebo 3.02, 95% confidence interval (CI) 2.37–3.84], whereas tolterodine was associated with the lowest risk of constipation (OR 1.36, 95% CI 1.01–1.85) [<xref ref-type="bibr" rid="bibr26-1756287212459549">Meek <italic>et al</italic>. 2011</xref>].</p>
</sec>
</sec>
<sec id="section9-1756287212459549">
<title>Efficacy and tolerability</title>
<sec id="section10-1756287212459549">
<title>Primary clinical trials</title>
<p>Key clinical trial design features and outcomes for studies investigating the use of imidafenacin in OAB are summarized in <xref ref-type="table" rid="table3-1756287212459549">Table 3</xref>.</p>
<table-wrap id="table3-1756287212459549" position="float">
<label>Table 3.</label>
<caption>
<p>Summary of the efficacy and tolerability of imidafenacin in key clinical trials investigating imidafenacin for the treatment of overactive bladder.</p>
</caption>
<graphic alternate-form-of="table3-1756287212459549" xlink:href="10.1177_1756287212459549-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Study design, patient population and characteristics (<italic>n</italic>)</th>
<th align="left">Dosage of imidafenacin</th>
<th align="left">Comparator (compound, dosage)</th>
<th align="left">Treatment duration</th>
<th align="left" colspan="4">Primary clinical finding</th>
<th align="left" colspan="4">Safety summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-finding study [<xref ref-type="bibr" rid="bibr14-1756287212459549">Homma <italic>et al</italic>. 2008</xref>]</td>
<td>Phase II, DB, PC, MC, R trial in men and women with OAB (401)</td>
<td rowspan="9">0.05 mg oral twice a day<break/>0.1 mg oral twice a day<break/>0.25 mg oral twice a day</td>
<td>pbo</td>
<td>12 weeks</td>
<td colspan="4">Mean change from baseline in the number of incontinence episodes per week at 12 weeks (%)</td>
<td colspan="4">Any AE (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>–59.81</td>
<td>–71.61<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–82.19<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–42.86</td>
<td>65.7</td>
<td>66.0</td>
<td>84.2</td>
<td>55.4</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of urgency incontinence episodes per week at 12 weeks (%)</td>
<td colspan="4">Dry mouth (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>–57.07</td>
<td>–75.67<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–74.20</td>
<td>–18.94</td>
<td>16.2</td>
<td>24.0</td>
<td>50.5</td>
<td>9.9</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of micturitions per day at 12 weeks</td>
<td colspan="4">Nasopharyngitis (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>–1.72</td>
<td>–1.59</td>
<td>–2.33<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–1.07</td>
<td>13.1</td>
<td>10.0</td>
<td>9.9</td>
<td>13.9</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the urine volume voided per micturition at 12 weeks (ml)</td>
<td colspan="4">Constipation (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
<td>0.05</td>
<td>0.1</td>
<td>0.25</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>14.06</td>
<td>9.89</td>
<td>26.11<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>2.29</td>
<td>2.0</td>
<td>9.0</td>
<td>8.9</td>
<td>4.0</td>
</tr>
<tr>
<td>Phase III study [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]</td>
<td>Phase III, DB, PC, MC, AC, R trial in men and women with OAB (781)</td>
<td>0.1 mg oral twice a day</td>
<td>Pbo propiverine 20 mg oral once a day</td>
<td>12 weeks</td>
<td colspan="4">Mean change from baseline in the number of incontinence episodes per week at 12 weeks (%)</td>
<td colspan="4">Any AE (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">imi</td>
<td>pro</td>
<td>pbo</td>
<td>imi</td>
<td>pro</td>
<td colspan="2">pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">–68.24<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>−73.09<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–49.50</td>
<td colspan="2">72.9</td>
<td>81.7</td>
<td>68.3</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of urgency incontinence episodes per week at 12 weeks (%)</td>
<td colspan="4">Dry mouth (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">imi</td>
<td>pro</td>
<td>pbo</td>
<td colspan="2">imi</td>
<td>pro</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">–69.47<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–75.53<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>–49.23</td>
<td colspan="2">31.5</td>
<td>39.9</td>
<td>13.8</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of micturitions per day at 12 weeks</td>
<td colspan="4">Nasopharyngitis (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">imi</td>
<td>pro</td>
<td>pbo</td>
<td colspan="2">Imi</td>
<td>pro</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">–1.52<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td>–1.80<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td>–1.08</td>
<td colspan="2">18.4</td>
<td>19.9</td>
<td>23.4</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the urine volume voided per micturition at 12 weeks (ml)</td>
<td colspan="4">Constipation (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">Imi</td>
<td>pro</td>
<td>pbo</td>
<td colspan="2">Imi</td>
<td>pro</td>
<td>pbo</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">19.35<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>36.07<xref ref-type="table-fn" rid="table-fn3-1756287212459549">*</xref></td>
<td>9.28</td>
<td colspan="2">11.8</td>
<td>13.7</td>
<td>7.6</td>
</tr>
<tr>
<td>Long term study [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>]</td>
<td>Phase III, OL, MC trial in men and women with OAB (478)</td>
<td>0.1 mg oral twice a day</td>
<td>N/A</td>
<td>52 wks</td>
<td colspan="4">Mean change from baseline in the number of incontinence episodes per week at 52 weeks (%)</td>
<td colspan="4">Any AE at 52 weeks (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">–83.51<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td colspan="4">90.4</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of urgency incontinence episodes per week at 52 weeks (%)</td>
<td colspan="4">Dry mouth (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">–84.21<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td colspan="4">40.2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the number of micturitions per day at 52 weeks</td>
<td colspan="4">Nasopharyngitis (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">–2.35<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td colspan="4">30.8</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">Mean change from baseline in the urine volume voided per micturition at 52 weeks (ml)</td>
<td colspan="4">Constipation (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="4">28.99<sup><xref ref-type="table-fn" rid="table-fn4-1756287212459549">$</xref></sup></td>
<td colspan="4">14.4</td>
</tr>
<tr>
<td>Dose increase study [<xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>]</td>
<td>Phase III, OL, MC trial in men and women with OAB (435)</td>
<td rowspan="4">0.1 mg oral twice a day<break/>0.2 mg oral twice a day</td>
<td>N/A</td>
<td>52 weeks</td>
<td colspan="4" rowspan="2">Mean change from baseline in the number of urgency incontinence episodes per week at 64 weeks (%)</td>
<td colspan="4">Dry mouth (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">0.1mg bid</td>
<td colspan="2">0.2mg bid</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td colspan="2" rowspan="2">0.1 mg twice a day</td>
<td colspan="2" rowspan="2">0.2 mg twice a day</td>
<td colspan="2">26.5</td>
<td colspan="2">53.3</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>64 weeks</td>
<td colspan="4">Constipation (%)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2" rowspan="2">NR</td>
<td colspan="2" rowspan="2">–77.85</td>
<td colspan="2">0.1 mg twice a day</td>
<td colspan="2">0.2 mg twice a day</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td colspan="2">9.9</td>
<td colspan="2">18.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1756287212459549">
<label>*</label>
<p>Significant difference (<italic>p</italic> ≤ 0.05) <italic>versus</italic> placebo.</p>
</fn>
<fn id="table-fn4-1756287212459549">
<label>$</label>
<p>Significant difference (<italic>p</italic> &lt; 0.05) <italic>versus</italic> baseline</p>
</fn>
<fn id="table-fn5-1756287212459549">
<p>AC, active control; AE, adverse event; CO, crossover; DB, double blind; imi, imidafenacin; MC, multicenter; N/A, not applicable; NR, not reported; OAB, overactive bladder; OL, open label; pbo, placebo; PC, placebo controlled; PG, parallel group; pro, propiverine; R, randomized.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section11-1756287212459549">
<title>Phase II</title>
<p>One phase II, randomized, double-blind, placebo-controlled, dose-finding study investigating the efficacy and tolerability of imidafenacin was conducted in 401 Japanese patients with OAB [<xref ref-type="bibr" rid="bibr14-1756287212459549">Homma <italic>et al</italic>. 2008</xref>]. Patients were randomized to oral imidafenacin 0.05, 0.1 and 0.25 mg twice daily or placebo.</p>
<p>Imidafenacin reduced urgency incontinence, voiding frequency and urinary urgency compared with placebo. Furthermore, the number of incontinence episodes (primary endpoint) in patients receiving imidafenacin 0.1 and 0.25 mg twice daily was significantly and dose-dependently reduced (<italic>p</italic> &lt; 0.0001) compared with placebo [<xref ref-type="bibr" rid="bibr14-1756287212459549">Homma <italic>et al</italic>. 2008</xref>].</p>
<p>Imidafenacin was generally well tolerated, with the incidences of adverse events following a dose-dependent pattern [<xref ref-type="bibr" rid="bibr14-1756287212459549">Homma <italic>et al</italic>. 2008</xref>]. The most common adverse event was dry mouth. Constipation, nasopharyngitis, abnormal sensations in the eye, dyspepsia, dizziness and vomiting were also reported [<xref ref-type="bibr" rid="bibr14-1756287212459549">Homma <italic>et al</italic>. 2008</xref>].</p>
<p>Considering the balance between the efficacy and safety of imidafenacin, a dose of 0.1 mg twice daily appeared to be a clinically appropriate dose for treating OAB. This dose was therefore selected for further evaluation in large-scale phase III studies.</p>
</sec>
<sec id="section12-1756287212459549">
<title>Phase III</title>
<p>Three phase III trials investigating imidafenacin for the treatment of OAB have been published [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>, <xref ref-type="bibr" rid="bibr12-1756287212459549">2009</xref>; <xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>]. The first was a randomized, double-blind, placebo- and propiverine-controlled trial which investigated the efficacy and tolerability of imidafenacin in 781 Japanese patients with OAB [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]. Patients were randomized to oral imidafenacin 0.1 mg twice daily, oral propiverine 20 mg once daily or placebo.</p>
<p>This study showed that imidafenacin was not inferior to propiverine for the reduction of incontinence episodes. Imidafenacin and propiverine significantly reduced the number of incontinence episodes per week <italic>versus</italic> placebo (–68.24% and −73.09% <italic>versus</italic> –49.50%, respectively; both <italic>p</italic> &lt; 0.0001) [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]. Similar reductions in urgency incontinence, voiding frequency and urinary urgency were also observed in patients who received imidafenacin and propiverine. Imidafenacin was well tolerated and associated with a significantly lower incidence of adverse events compared with propiverine (<italic>p</italic> = 0.0101) [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]. The most common adverse event was dry mouth: reported in 31.5% and 39.9% of patients receiving imidafenacin and propiverine, respectively (<italic>p</italic> = 0.0302).</p>
<p>An open-label study investigating the long-term tolerability and efficacy of imidafenacin 0.1 mg twice daily showed that the favorable safety, tolerability and efficacy observed with imidafenacin was maintained over 52 weeks in 478 Japanese patients with OAB [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>]. Again, the most commonly reported adverse event was dry mouth (40.2% of patients) [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>]. In this study, 41 serious adverse events and one death in 35 patients were reported [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>]. Forty of the serious adverse events were considered not related to the study drug; whereas one serious adverse event (acute glaucoma) was considered possibly related to imidafenacin [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>]. The death (ischemic cardiac failure resulting from concurrent hypertension) was considered not related to the study drug [<xref ref-type="bibr" rid="bibr11-1756287212459549">Homma and Yamaguchi, 2008</xref>].</p>
<p>Another open-label study investigating the long-term tolerability and efficacy of imidafenacin 0.2 mg twice daily was conducted in 435 Japanese patients with OAB who did not have an adequate respond to imidafenacin 0.1 mg twice daily [<xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>]. At the higher dosage, imidafenacin was relatively well tolerated, with dry mouth and constipation reported in 53.3% and 18.7% of patients receiving 0.2 mg twice daily and 26.5% and 9.9% of patients receiving 0.1 mg twice daily, respectively [<xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>]. Furthermore, imidafenacin 0.2 mg twice daily improved the number of urgency incontinence episodes per week after 16 weeks of treatment compared with 0.1 mg twice daily [<xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>]. The authors concluded that if the effect of imidafenacin 0.1 mg twice daily is insufficient, a dose increase to 0.2 mg twice daily could be effective and safe, providing additional options for managing patients who are not satisfied with the effect of the standard dose of imidafenacin [<xref ref-type="bibr" rid="bibr48-1756287212459549">Yamaguchi and Homma, 2009</xref>].</p>
</sec>
</sec>
<sec id="section13-1756287212459549">
<title>Other clinical trials</title>
<sec id="section14-1756287212459549">
<title>Overactive bladder</title>
<p>The LIST study was a randomized, open-label, 52-week study comparing the efficacy and tolerability of imidafenacin (0.1 mg twice daily) and solifenacin (5 mg once daily) in patients with OAB [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. The results showed no significant difference between the two anticholinergics in terms of efficacy over 12 and 52 weeks, but the severity and incidence of drug-induced adverse events differed between treatment groups (<xref ref-type="table" rid="table4-1756287212459549">Table 4</xref>) [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. The severity of dry mouth associated with imidafenacin was significantly milder than that in solifenacin recipients: four patients (20%) receiving solifenacin reported severe dry mouth compared with none receiving imidafenacin [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. Furthermore, the incidence of constipation was also significantly (<italic>p</italic> = 0.0013) lower with imidafenacin than solifenacin [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. The authors proposed that the differences in the observed tolerability of these two anticholinergics may be due to differences in pharmacokinetics and binding selectivity [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>].</p>
<table-wrap id="table4-1756287212459549" position="float">
<label>Table 4.</label>
<caption>
<p>Summary of the LIST study by Zaitsu and colleagues [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>].</p>
</caption>
<graphic alternate-form-of="table4-1756287212459549" xlink:href="10.1177_1756287212459549-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left" colspan="5">The LIST Study (Japan University Hospital Medical Information Network record number UMIN000004354) [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td colspan="5">Open, randomized, parallel group, active controlled</td>
</tr>
<tr>
<td>Patient population and characteristics (<italic>n</italic>)</td>
<td colspan="5">Japanese patients with untreated overactive bladder (<italic>n</italic> = 41)</td>
</tr>
<tr>
<td/>
<td colspan="5">Age: ≥50 to &lt;80 years (mean 70 years)</td>
</tr>
<tr>
<td>Treatment details</td>
<td colspan="5">Imidafenacin 0.1 mg twice daily (<italic>n</italic> = 21)</td>
</tr>
<tr>
<td/>
<td colspan="5">Discharged from the study due to lack of response, tolerability or other issues (<italic>n</italic> = 4)</td>
</tr>
<tr>
<td>Comparator</td>
<td colspan="5">Solifenacin 5 mg/day (<italic>n</italic> = 20)</td>
</tr>
<tr>
<td/>
<td colspan="5">Discharged from the study due to lack of response, tolerability or other issues (<italic>n</italic> = 2)</td>
</tr>
<tr>
<td>Treatment duration</td>
<td colspan="5">52 weeks</td>
</tr>
<tr>
<td>Result summary</td>
<td colspan="2">Imidafenacin</td>
<td colspan="2">Solifenacin</td>
<td><italic>p</italic> value</td>
</tr>
<tr>
<td/>
<td>baseline</td>
<td>52 weeks</td>
<td>baseline</td>
<td>52 weeks</td>
<td/>
</tr>
<tr>
<td> OABSS</td>
<td>9.0 ± 1.3</td>
<td>4.3 ± 2.8</td>
<td>8.9 ± 2.6</td>
<td>5.1 ± 2.1</td>
<td>0.6384</td>
</tr>
<tr>
<td> KHQ</td>
<td colspan="5">Imidafenacin significantly improved all KHQ subscores from baseline. These improvements were similar to those observed with solifenacin</td>
</tr>
<tr>
<td>AE summary (% patients)</td>
<td colspan="2">Imidafenacin</td>
<td colspan="2">Solifenacin</td>
<td><italic>p</italic> value</td>
</tr>
<tr>
<td> Any AE</td>
<td colspan="2">76.2</td>
<td colspan="2">95.0</td>
<td/>
</tr>
<tr>
<td> Dry mouth</td>
<td colspan="2">71.4</td>
<td colspan="2">90.0</td>
<td>0.2379</td>
</tr>
<tr>
<td> Constipation</td>
<td colspan="2">14.3</td>
<td colspan="2">65.0</td>
<td>0.0013</td>
</tr>
<tr>
<td> Blurred vision</td>
<td colspan="2">9.5</td>
<td colspan="2">35.0</td>
<td>0.0670</td>
</tr>
<tr>
<td colspan="6">Time to first AE at 52 weeks:</td>
</tr>
<tr>
<td> Dry mouth</td>
<td colspan="5">the time to the first adverse event caused by solifenacin increased after 12 weeks, but not by imidafenacin(log rank test: <italic>p</italic> = 0.0412).</td>
</tr>
<tr>
<td> Constipation</td>
<td colspan="5">the time to the first adverse event caused by solifenacin increased after 12 weeks, but not by imidafenacin(log rank test: <italic>p</italic> = 0.0017).</td>
</tr>
<tr>
<td> Blurred vision</td>
<td colspan="5">No significant difference between treatment groups (log rank test: <italic>p</italic> = 0.0686)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1756287212459549">
<p>AE, adverse event; KHQ, King’s Health Questionnaire; OABSS, overactive bladder symptoms score.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-1756287212459549">
<title>Nocturia</title>
<p>Nocturia, the need to get up in the night to urinate, is a common symptom of OAB. A number of studies investigating the effects of imidafenacin on nocturia and sleep quality have been conducted [<xref ref-type="bibr" rid="bibr43-1756287212459549">Takeda <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr28-1756287212459549">Nagaoka <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr40-1756287212459549">Shimizu <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr24-1756287212459549">Kuratsukuri <italic>et al</italic>. 2012</xref>], which highlight that imidafenacin is a viable option for improving sleep quality and duration in patients with OAB and nocturia.</p>
<p>The Evaluation of Anticholinergics in Patients with OAB and Nocturia for Cared-health (EPOC) study investigated the effects of imidafenacin 0.1 mg twice daily on sleep in patients with OAB [<xref ref-type="bibr" rid="bibr43-1756287212459549">Takeda <italic>et al</italic>. 2009</xref>]. This study found that after 8 weeks of treatment there was a correlation between the improvement observed in nocturia, assessed using a frequency volume chart, and sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI; correlation coefficient 0.358) [<xref ref-type="bibr" rid="bibr43-1756287212459549">Takeda <italic>et al</italic>. 2009</xref>].</p>
<p>This was supported by the FUSION study which investigated the effects of imidafenacin on sleep disorders and health-related quality of life (HRQOL) in patients with OAB and nocturia [<xref ref-type="bibr" rid="bibr28-1756287212459549">Nagaoka <italic>et al</italic>. 2011</xref>]. Imidafenacin was associated with improved sleep parameters and HRQOL.</p>
<p>The GOOD-NIGHT study investigated the efficacy and tolerability of imidafenacin and α-blocker therapy in men with benign prostatic hyperplasia and OAB [<xref ref-type="bibr" rid="bibr24-1756287212459549">Kuratsukuri <italic>et al</italic>. 2012</xref>]. This open-label study in 130 men who had been receiving an α-blocker for at least 4 weeks and were experiencing nocturia randomized patients to an α blocker alone, an α blocker with imidafenacin 0.1 mg twice daily or an α blocker with imidafenacin 0.1 mg once daily [<xref ref-type="bibr" rid="bibr24-1756287212459549">Kuratsukuri <italic>et al</italic>. 2012</xref>]. Adding imidafenacin 0.1 mg twice daily and 0.1 mg once daily (administered in the evening) to α-blocker therapy was associated with a reduction in night-time voiding (<italic>p</italic> = 0.0014 and 0.0143) and an improvement in Nocturia Quality Of Life Questionnaire scores (<italic>p</italic> = 0.0013 in imidafenacin 0.1 mg twice daily group only) after 8 weeks of treatment compared with α-blocker therapy alone [<xref ref-type="bibr" rid="bibr24-1756287212459549">Kuratsukuri <italic>et al</italic>. 2012</xref>].</p>
<p>Finally, a study in 140 older patients with OAB showed that imidafenacin 0.1 mg twice daily improved nocturnal polyuria after 4 weeks of treatment [<xref ref-type="bibr" rid="bibr40-1756287212459549">Shimizu <italic>et al</italic>. 2011</xref>]. In patients aged 65–74 years and patients aged at least 75 years, imidafenacin was associated with a significant (<italic>p</italic> &lt; 0.001) reduction in the Overactive Bladder Symptom Score (OABSS) [<xref ref-type="bibr" rid="bibr40-1756287212459549">Shimizu <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section16-1756287212459549">
<title>Benign prostatic hyperplasia</title>
<p>Imidafenacin has demonstrated utility for the management of symptoms in patients with benign prostatic hyperplasia and OAB. The GOOD-NIGHT study found that adding imidafenacin 0.1 mg twice daily and 0.1 mg once daily to α-blocker therapy not only improved nocturia (as discussed previously) but was also associated with an improvement in International Prostate Symptom Score Quality of Life (IPSS-QOL) scores (<italic>p</italic> = 0.0040 and 0.0038) after 8 weeks of treatment compared with α-blocker therapy alone [<xref ref-type="bibr" rid="bibr24-1756287212459549">Kuratsukuri <italic>et al</italic>. 2012</xref>].</p>
</sec>
<sec id="section17-1756287212459549">
<title>Women</title>
<p>Imidafenacin improved OAB symptoms and quality of life, assessed using the OABSS and the International Consultation on Incontinence Questionnaire – Short Form, respectively, in a trial investigating the efficacy and safety of imidafenacin in women with urge and mixed urinary incontinence [<xref ref-type="bibr" rid="bibr39-1756287212459549">Shimada <italic>et al</italic>. 2011b</xref>]. Imidafenacin was also well tolerated [<xref ref-type="bibr" rid="bibr39-1756287212459549">Shimada <italic>et al</italic>. 2011b</xref>]: no serious adverse events were reported and the incidence of any adverse event was low (7.9%).</p>
</sec>
<sec id="section18-1756287212459549">
<title>Older people</title>
<p>Unpublished results from phase II and phase III, double-blind, placebo-controlled trials indicate that age does not appear to influence the efficacy or tolerability of imidafenacin. Furthermore, in a prospective clinical trial in 140 patients with OAB who received imidafenacin 0.1 mg twice daily for 4 weeks, there was no difference between patients aged 65–74 years old and patients aged at least 75 years with regards to the reduction in OABSS scores (from 8.5 ± 3.2 to 5.2 ± 3.4 and from 8.9 ± 3.0 to 5.5 ± 3.1, respectively; both <italic>p</italic> &lt; 0.001) [<xref ref-type="bibr" rid="bibr40-1756287212459549">Shimizu <italic>et al</italic>. 2011</xref>].</p>
</sec>
</sec>
</sec>
<sec id="section19-1756287212459549">
<title>Clinical benefits of imidafenacin: a summary</title>
<sec id="section20-1756287212459549">
<title>Imidafenacin is clinically effective</title>
<p>Imidafenacin has been shown to be a potent anticholinergic in <italic>in vitro</italic> studies [<xref ref-type="bibr" rid="bibr20-1756287212459549">Kobayashi <italic>et al</italic>. 2007a</xref>, <xref ref-type="bibr" rid="bibr47-1756287212459549">Yamada <italic>et al</italic>. 2011b</xref>]. Furthermore, in a phase III clinical trial, imidafenacin was associated with a significant improvement in OAB compared with placebo: this benefit was similar (not inferior) to the efficacy of propiverine 20 mg/day in this trial [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>]. Imidafenacin is also associated with a similar efficacy to solifenacin. In the Global Assessment Study of Anti-cholinergics on Efficacy and Tolerability for Patients with OAB study, both imidafenacin and solifenacin were associated with significant improvements in the total and four subscores of the OABSS [<xref ref-type="bibr" rid="bibr29-1756287212459549">Nishii <italic>et al</italic>. 2011</xref>]: the LIST study showed similar results [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. Finally, the efficacy of imidafenacin for the treatment of OAB is immediate: efficacy is observed 3 days after the initiation of treatment [<xref ref-type="bibr" rid="bibr23-1756287212459549">Kubota <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr19-1756287212459549">Kitagawa <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section21-1756287212459549">
<title>Imidafenacin is safe and well tolerated for long-term treatment</title>
<p>Studies have demonstrated that imidafenacin is associated with a favorable short-term tolerability profile compared with propiverine [<xref ref-type="bibr" rid="bibr12-1756287212459549">Homma and Yamaguchi, 2009</xref>] and a favorable long-term tolerability profile compared with solifenacin [<xref ref-type="bibr" rid="bibr51-1756287212459549">Zaitsu <italic>et al</italic>. 2011</xref>]. In addition, in a study conducted by Kase and colleagues, imidafenacin was associated with the shortest duration of dry mouth symptoms compared with other anticholinergics [<xref ref-type="bibr" rid="bibr18-1756287212459549">Kase <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section22-1756287212459549">
<title>Adjustable dosing</title>
<p>One unique feature of imidafenacin treatment is the ability to easily adjust dosing. Some patients with OAB only experience symptoms during part of the day. Imidafenacin is given as a twice-daily oral tablet and this enables treatment to be administered at a time most suitable to target the symptoms when they happen. For example, in patients with nocturia, 0.3 mg/day imidafenacin can be administered as 0.1 mg in the morning and 0.2 mg in the evening. Furthermore, a new oral disintegrating tablet formulation has been developed that allows for administration without water [<xref ref-type="bibr" rid="bibr35-1756287212459549">Shimada <italic>et al</italic>. 2011a</xref>], which could help patients to control drinking behavior and limit fluid intake.</p>
</sec>
</sec>
<sec id="section23-1756287212459549" sec-type="conclusions">
<title>Conclusions</title>
<p>OAB is a chronic disease. Therefore, the ideal treatment should have good long-term efficacy and tolerability. Imidafenacin meets these criteria, making it is a useful anticholinergic for the treatment of OAB.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Simone Boniface of <italic>in</italic>Science Communications, Springer Healthcare, who provided copyediting and journal styling prior to submission. We are grateful for the help and support of our colleague at Kanto Rosai Hospital for the LIST study.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abrams</surname><given-names>P.</given-names></name>
<name><surname>Cardozo</surname><given-names>L.</given-names></name>
<name><surname>Chapple</surname><given-names>C.</given-names></name>
<name><surname>Serdarevic</surname><given-names>D.</given-names></name>
<name><surname>Hargreaves</surname><given-names>K.</given-names></name>
<name><surname>Khullar</surname><given-names>V.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome</article-title>. <source>Int J Urol</source> <volume>13</volume>: <fpage>692</fpage>–<lpage>698</lpage>.</citation>
</ref>
<ref id="bibr2-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abrams</surname><given-names>P.</given-names></name>
<name><surname>Cardozo</surname><given-names>L.</given-names></name>
<name><surname>Fall</surname><given-names>M.</given-names></name>
<name><surname>Griffiths</surname><given-names>D.</given-names></name>
<name><surname>Rosier</surname><given-names>P.</given-names></name>
<name><surname>Ulmsten</surname><given-names>U.</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</article-title>. <source>Neurourol Urodyn</source> <volume>21</volume>: <fpage>167</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr3-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abrams</surname><given-names>P.</given-names></name>
<name><surname>Kelleher</surname><given-names>C.</given-names></name>
<name><surname>Kerr</surname><given-names>L.</given-names></name>
<name><surname>Rogers</surname><given-names>R.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Overactive bladder significantly affects quality of life</article-title>. <source>Am J Manag Care</source> <volume>6</volume>: <fpage>S580</fpage>–<lpage>S590</lpage>.</citation>
</ref>
<ref id="bibr4-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersson</surname><given-names>K.E.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Antimuscarinics for treatment of overactive bladder</article-title>. <source>Lancet Neurol</source> <volume>3</volume>: <fpage>46</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr5-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cardozo</surname><given-names>L.</given-names></name>
<name><surname>Castro-Diaz</surname><given-names>D.</given-names></name>
<name><surname>Gittelman</surname><given-names>M.</given-names></name>
<name><surname>Ridder</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin</article-title>. <source>Int Urogynecol J Pelvic Floor Dysfunct</source> <volume>17</volume>: <fpage>512</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr6-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapple</surname><given-names>C.</given-names></name>
<name><surname>Cardozo</surname><given-names>L.</given-names></name>
<name><surname>Steers</surname><given-names>W.</given-names></name>
<name><surname>Govier</surname><given-names>F.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Solifenacin significantly improves all symptoms of overactive bladder syndrome</article-title>. <source>Int J Clin Pract</source> <volume>60</volume>: <fpage>959</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr7-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapple</surname><given-names>C.</given-names></name>
<name><surname>Yamanishi</surname><given-names>T.</given-names></name>
<name><surname>Chess-Williams</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Muscarinic receptor subtypes and management of the overactive bladder</article-title>. <source>Urology</source> <volume>60</volume>: <fpage>82</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr8-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diefenbach</surname><given-names>K.</given-names></name>
<name><surname>Jaeger</surname><given-names>K.</given-names></name>
<name><surname>Wollny</surname><given-names>A.</given-names></name>
<name><surname>Penzel</surname><given-names>T.</given-names></name>
<name><surname>Fietze</surname><given-names>I.</given-names></name>
<name><surname>Roots</surname><given-names>I.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Effect of tolterodine on sleep structure modulated by CYP2D6 genotype</article-title>. <source>Sleep Med</source> <volume>9</volume>: <fpage>579</fpage>–<lpage>582</lpage>.</citation>
</ref>
<ref id="bibr9-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herbison</surname><given-names>P.</given-names></name>
<name><surname>Hay-Smith</surname><given-names>J.</given-names></name>
<name><surname>Ellis</surname><given-names>G.</given-names></name>
<name><surname>Moore</surname><given-names>K.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review</article-title>. <source>BMJ</source> <volume>326</volume>: <fpage>841</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr10-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Paick</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Kawabe</surname><given-names>K.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial</article-title>. <source>BJU Int</source> <volume>92</volume>: <fpage>741</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr11-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>O.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder</article-title>. <source>Int J Urol</source> <volume>15</volume>: <fpage>986</fpage>–<lpage>991</lpage>.</citation>
</ref>
<ref id="bibr12-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>O.</given-names></name>
</person-group> (<year>2009</year>) <article-title>A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder</article-title>. <source>Int J Urol</source> <volume>16</volume>: <fpage>499</fpage>-<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr13-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>O.</given-names></name>
<name><surname>Hayashi</surname><given-names>K.</given-names></name>
</person-group> (<year>2005</year>) <article-title>An epidemiological survey of overactive bladder symptoms in Japan</article-title>. <source>BJU Int</source> <volume>96</volume>: <fpage>1314</fpage>–<lpage>1318</lpage>.</citation>
</ref>
<ref id="bibr14-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>O.</given-names></name>
</person-group> (<year>2008</year>) <article-title>A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder</article-title>. <source>Int J of Urol</source> <volume>15</volume>: <fpage>809</fpage>–<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr15-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Kato</surname><given-names>A.</given-names></name>
<name><surname>Fujino</surname><given-names>T.</given-names></name>
<name><surname>Okura</surname><given-names>T.</given-names></name>
<name><surname>Yoshida</surname><given-names>K.</given-names></name>
<name><surname>Nanri</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Muscarinic receptor binding and plasma drug concentration after the oral administration of propiverine in mice</article-title>. <source>Low Urin Tract Symptoms</source> <volume>2</volume>: <fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr16-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanayama</surname><given-names>N.</given-names></name>
<name><surname>Kanari</surname><given-names>C.</given-names></name>
<name><surname>Masuda</surname><given-names>Y.</given-names></name>
<name><surname>Ohmori</surname><given-names>S.</given-names></name>
<name><surname>Ooie</surname><given-names>T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Drug–drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes</article-title>. <source>Xenobiotica</source> <volume>37</volume>: <fpage>139</fpage>.</citation>
</ref>
<ref id="bibr17-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaneko</surname><given-names>S.</given-names></name>
<name><surname>Tabata</surname><given-names>K.</given-names></name>
<name><surname>Kyuno</surname><given-names>H.</given-names></name>
<name><surname>Ishii</surname><given-names>D.</given-names></name>
<name><surname>Kurosaka</surname><given-names>S.</given-names></name>
<name><surname>Nishi</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2011</year>) [<article-title>Efficacy of imidafenacin for chronic stroke patients with overactive bladder</article-title>]. <source>Jpn J Urol Surg</source> <volume>24</volume>: <fpage>1481</fpage>–<lpage>1488</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr18-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kase</surname><given-names>H.</given-names></name>
<name><surname>Arak</surname><given-names>S.</given-names></name>
<name><surname>Kitamura</surname><given-names>T.</given-names></name>
<name><surname>Koyama</surname><given-names>Y.</given-names></name>
<name><surname>Inowa</surname><given-names>T.</given-names></name>
<name><surname>Ishimaru</surname><given-names>Y.</given-names></name>
<etal/></person-group>. (<year>2010</year>) [<article-title>A comparative study of anticholinergic drugs used for overactive bladder in routine clinical practice, with a focus on dry mouth</article-title>]. <source>Jpn J Urol Surg</source> <volume>23</volume>: <fpage>1299</fpage>–<lpage>1306</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr19-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitagawa</surname><given-names>Y.</given-names></name>
<name><surname>Kuribayashi</surname><given-names>M.</given-names></name>
<name><surname>Narimoto</surname><given-names>K.</given-names></name>
<name><surname>Kawaguchi</surname><given-names>S.</given-names></name>
<name><surname>Yaegashi</surname><given-names>H.</given-names></name>
<name><surname>Namiki</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Immediate effect on overactive bladder symptoms following administration of imidafenacin</article-title>. <source>Urol Int</source> <volume>86</volume>: <fpage>330</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr20-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>F.</given-names></name>
<name><surname>Yageta</surname><given-names>Y.</given-names></name>
<name><surname>Segawa</surname><given-names>M.</given-names></name>
<name><surname>Matsuzawa</surname><given-names>S.</given-names></name>
</person-group> (<year>2007a</year>) <article-title>Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors: high affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland</article-title>. <source>Arzneimittelforschung</source> <volume>57</volume>: <fpage>92</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr21-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>F.</given-names></name>
<name><surname>Yageta</surname><given-names>Y.</given-names></name>
<name><surname>Yamazaki</surname><given-names>T.</given-names></name>
<name><surname>Wakabayashi</surname><given-names>E.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
<name><surname>Segawa</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2007b</year>) <article-title>Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats: comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task</article-title>. <source>Arzneimittelforschung</source> <volume>57</volume>: <fpage>147</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr22-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koyanagi</surname><given-names>T.</given-names></name>
<name><surname>Maru</surname><given-names>A.</given-names></name>
<name><surname>Taniguchi</surname><given-names>K.</given-names></name>
<name><surname>Shinno</surname><given-names>Y.</given-names></name>
<name><surname>Takamatsu</surname><given-names>T.</given-names></name>
<name><surname>Morita</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>1986</year>) [<article-title>Clinical evaluation of oxybutynin hydrochloride (KL007 tablets) for the treatment of neurogenic bladder and unstable bladder: a parallel double-blind controlled study with placebo</article-title>]. <source>Nishi Nihon Hinyokika</source> <volume>48</volume>: <fpage>1051</fpage>–<lpage>1072</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr23-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kubota</surname><given-names>Y.</given-names></name>
<name><surname>Sasaki</surname><given-names>S.</given-names></name>
<name><surname>Kojima</surname><given-names>Y.</given-names></name>
<name><surname>Hayase</surname><given-names>M.</given-names></name>
<name><surname>Imura</surname><given-names>M.</given-names></name>
<name><surname>Shibata</surname><given-names>Y.</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Early efficacy and safety of imidafenacin in patients with OAB</article-title>. <source>Jpn J Urol Surg</source> <volume>23</volume>: <fpage>827</fpage>–<lpage>832</lpage>.</citation>
</ref>
<ref id="bibr24-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuratsukuri</surname><given-names>K.</given-names></name>
<name><surname>Tsujimura</surname><given-names>A.</given-names></name>
<name><surname>Akino</surname><given-names>H.</given-names></name>
<name><surname>Oguchi</surname><given-names>N.</given-names></name>
<name><surname>Kitagawa</surname><given-names>Y.</given-names></name>
<name><surname>Segawa</surname><given-names>N.</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with OAB using an alpha-blocker combined with a novel anticholinergic, imidafenacin</article-title>. In <source>GOOD-NIGHT Study. Eur Urol Suppl</source> <volume>11</volume>: <fpage>E745</fpage>–<lpage>U584</lpage>.</citation>
</ref>
<ref id="bibr25-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maruyama</surname><given-names>S.</given-names></name>
<name><surname>Hasuike</surname><given-names>N.</given-names></name>
<name><surname>Suzuki</surname><given-names>K.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder</article-title>. <source>Naunyn-Schmiedebergs Arch Pharmacol</source> <volume>377</volume>: <fpage>463</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr26-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meek</surname><given-names>P.</given-names></name>
<name><surname>Evang</surname><given-names>S.</given-names></name>
<name><surname>Tadrous</surname><given-names>M.</given-names></name>
<name><surname>Roux-Lirange</surname><given-names>D.</given-names></name>
<name><surname>Triller</surname><given-names>D.</given-names></name>
<name><surname>Gumustop</surname><given-names>B.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials</article-title>. <source>Dig Dis Sci</source> <volume>56</volume>: <fpage>7</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr27-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milsom</surname><given-names>I.</given-names></name>
<name><surname>Abrams</surname><given-names>P.</given-names></name>
<name><surname>Cardozo</surname><given-names>L.</given-names></name>
<name><surname>Roberts</surname><given-names>R.</given-names></name>
<name><surname>Thuroff</surname><given-names>J.</given-names></name>
<name><surname>Wein</surname><given-names>A.J.</given-names></name>
</person-group> (<year>2001</year>) <article-title>How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study</article-title>. <source>BJU Int</source> <volume>87</volume>: <fpage>760</fpage>–<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr28-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagaoka</surname><given-names>A.</given-names></name>
<name><surname>Sakurai</surname><given-names>T.</given-names></name>
<name><surname>Naito</surname><given-names>S.</given-names></name>
<name><surname>Nishida</surname><given-names>H.</given-names></name>
<name><surname>Kawazoe</surname><given-names>H.</given-names></name>
<name><surname>Tsukigi</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2011</year>) [<article-title>Sleep disorders and HRQOL were significantly improved by imidafenacin, an anticholinergic agent, in OAB patients with nocturia</article-title>]. <source>Jpn J Urol Surg</source> <volume>24</volume>: <fpage>1649</fpage>–<lpage>1656</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr29-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishii</surname><given-names>H.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>K.</given-names></name>
<name><surname>Fukai</surname><given-names>K.</given-names></name>
<name><surname>Sakamoto</surname><given-names>S.</given-names></name>
<name><surname>Ito</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) [<article-title>Imidafenacin, a novel anticholinergic agent with low side effects, shows equivalent efficacy to solifenacin in overactive bladder patients – GAP (Global Assessment Study of Anti-cholinergics on Efficacy and Tolerability for Patients with OAB) study</article-title>]. <source>Jpn J Urol Surg</source> <volume>24</volume>: <fpage>1489</fpage>–<lpage>1500</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr30-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohtake</surname><given-names>A.</given-names></name>
<name><surname>Yanai-Inamura</surname><given-names>H.</given-names></name>
<name><surname>Ukai</surname><given-names>M.</given-names></name>
<name><surname>Noguchi</surname><given-names>Y.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Sasamata</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2008</year>) [<article-title>In vitro and in vivo bladder-selectivity profile of solifenacin succinate (Vesicare<sup>®</sup>) developed as a new therapeutic agent for overactive bladder</article-title>]. <source>Jpn Pharmacol Ther</source> <volume>36</volume>: <fpage>119</fpage>–<lpage>128</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr31-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oki</surname><given-names>T.</given-names></name>
<name><surname>Maruyama</surname><given-names>S.</given-names></name>
<name><surname>Takagi</surname><given-names>Y.</given-names></name>
<name><surname>Yamamura</surname><given-names>H.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice</article-title>. <source>Eur J Pharmacol</source> <volume>529</volume>: <fpage>157</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr32-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oki</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>S.</given-names></name>
<name><surname>Miyata</surname><given-names>K.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice</article-title>. <source>Br J Pharmacol</source> <volume>145</volume>: <fpage>219</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr33-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakakibara</surname><given-names>R.</given-names></name>
<name><surname>Tateno</surname><given-names>F.</given-names></name>
<name><surname>Takahashi</surname><given-names>O.</given-names></name>
<name><surname>Sugiyama</surname><given-names>M.</given-names></name>
<name><surname>Kishi</surname><given-names>M.</given-names></name>
<name><surname>Ogawa</surname><given-names>E.</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Evaluation of imidafenacin on urinary sensation and brain function using real-time measurement of oxyhemoglobin concentration changes in frontal micturition area of OAB patients</article-title>. <source>Neurourol Urodyn</source> <volume>30</volume>: <fpage>850</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr34-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>H.</given-names></name>
<name><surname>Hasunuma</surname><given-names>T.</given-names></name>
<name><surname>Hirahara</surname><given-names>Y.</given-names></name>
<name><surname>Ishikawa</surname><given-names>N.</given-names></name>
</person-group> (<year>2007a</year>) [<article-title>Pharmacokinetic study of imidafenacin (KRP-197/ONO-8025): pharmacokinetics of single oral administration of imidafenacin tablet 0.1 mg and food-effect on its oral absorption in healthy male volunteers</article-title>]. <source>J Clin Ther Med</source> <volume>23</volume>: <fpage>273</fpage>–<lpage>285</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr35-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>H.</given-names></name>
<name><surname>Kobayashi</surname><given-names>H.</given-names></name>
<name><surname>Arai</surname><given-names>M.</given-names></name>
<name><surname>Shimamoto</surname><given-names>K.</given-names></name>
</person-group> (<year>2011a</year>) [<article-title>Pharmacokinetic study on imidafenacin 0.1 mg oral disintegrating tablets: evaluation of bioequivalence of oral disintegrating tablets and conventional tablets and assessment of oral mucosal absorption in healthy male volunteers</article-title>]. <source>J Clin Ther Med</source> <volume>27</volume>: <fpage>171</fpage>–<lpage>182</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr36-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>H.</given-names></name>
<name><surname>Shibata</surname><given-names>H.</given-names></name>
<name><surname>Hirahara</surname><given-names>Y.</given-names></name>
<name><surname>Masuda</surname><given-names>Y.</given-names></name>
</person-group> (<year>2007b</year>) [<article-title>Phase I clinical study of imidafenacin (KRP-197/ONO-8025): safety and pharmacokinetics of repeated dosage of imidafenacin in healthy subjects</article-title>]. <source>J Clin Ther Med</source> <volume>23</volume>: <fpage>249</fpage>–<lpage>262</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr37-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>H.</given-names></name>
<name><surname>Shibata</surname><given-names>H.</given-names></name>
<name><surname>Hirahara</surname><given-names>Y.</given-names></name>
<name><surname>Masuda</surname><given-names>Y.</given-names></name>
</person-group> (<year>2007c</year>) [<article-title>Investigation on safety and pharmacokinetic profile of imidafenacin (KRP-197/ONO-8025) after single administration in the elderly</article-title>]. <source>J Clin Ther Med</source> <volume>23</volume>: <fpage>263</fpage>–<lpage>272</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr38-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>H.</given-names></name>
<name><surname>Yafune</surname><given-names>A.</given-names></name>
<name><surname>Shibata</surname><given-names>H.</given-names></name>
<name><surname>Hirahara</surname><given-names>Y.</given-names></name>
<name><surname>Masuda</surname><given-names>Y.</given-names></name>
</person-group> (<year>2007d</year>) [<article-title>Phase I clinical study of imidafenacin (KRP-197/ONO-8025): single-dose safety and pharmacokinetics of imidafenacin in healthy subjects</article-title>]. <source>J Clin Ther Med</source> <volume>23</volume>: <fpage>233</fpage>–<lpage>248</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr39-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimada</surname><given-names>M.</given-names></name>
<name><surname>Inoue</surname><given-names>K.</given-names></name>
<name><surname>Okumura</surname><given-names>T.</given-names></name>
<name><surname>Aoki</surname><given-names>S.</given-names></name>
<name><surname>Ogawa</surname><given-names>Y.</given-names></name>
<name><surname>Matsubara</surname><given-names>E.</given-names></name>
<etal/></person-group>. (<year>2011b</year>) [<article-title>Efficacy and safety of imidafenacin in female patients with urge and mixed urinary incontinence</article-title>]. <source>Hinyokika Kiyo</source> <volume>57</volume>: <fpage>1</fpage>–<lpage>6</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr40-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>N.</given-names></name>
<name><surname>Minami</surname><given-names>T.</given-names></name>
<name><surname>Uemura</surname><given-names>H.</given-names></name>
<name><surname>Nishioka</surname><given-names>T.</given-names></name>
<name><surname>Tahara</surname><given-names>H.</given-names></name>
<name><surname>Esa</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2011</year>) [<article-title>A study of the efficacy and safety of imidafenacin in younger and older elderly patients with overactive bladder</article-title>]. <source>Jpn J Urol Surg</source> <volume>24</volume>: <fpage>639</fpage>–<lpage>648</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr41-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staskin</surname><given-names>D.</given-names></name>
<name><surname>Te</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence</article-title>. <source>BJU Int</source> <volume>97</volume>: <fpage>1256</fpage>–<lpage>1261</lpage>.</citation>
</ref>
<ref id="bibr42-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>W.</given-names></name>
<name><surname>Van Rooyen</surname><given-names>J.</given-names></name>
<name><surname>Cundiff</surname><given-names>G.</given-names></name>
<name><surname>Abrams</surname><given-names>P.</given-names></name>
<name><surname>Herzog</surname><given-names>A.</given-names></name>
<name><surname>Corey</surname><given-names>R.</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>Prevalence and burden of overactive bladder in the united states</article-title>. <source>World J Urol</source> <volume>20</volume>: <fpage>327</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr43-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takeda</surname><given-names>M.</given-names></name>
<name><surname>Takahashi</surname><given-names>S.</given-names></name>
<name><surname>Nishizawa</surname><given-names>O.</given-names></name>
<name><surname>Gotoh</surname><given-names>M.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) [<article-title>Imidafenacin, a novel anticholinergic, significantly improves both nocturia and sleep disorders in OAB patients: EPOCH (Evaluation of anticholinergics in Patients with Overactive bladder and nocturia for Care Health) study</article-title>]. <source>Jpn J Urol Surg</source> <volume>22</volume>: <fpage>53</fpage>–<lpage>60</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr44-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takei</surname><given-names>M.</given-names></name>
<name><surname>Homma</surname><given-names>Y.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder (in Japanese) patients</article-title>. <source>Int J Urol</source> <volume>12</volume>: <fpage>456</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr45-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wein</surname><given-names>A.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Pharmacological agents for the treatment of urinary incontinence due to overactive bladder</article-title>. <source>Expert Opin Investig Drugs</source> <volume>10</volume>: <fpage>65</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr46-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>S.</given-names></name>
<name><surname>Ogoda</surname><given-names>M.</given-names></name>
<name><surname>Yoshida</surname><given-names>A.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Tsukada</surname><given-names>H.</given-names></name>
</person-group> (<year>2011a</year>) [<article-title>Perspective of bladder selectivity based on <italic>in vivo</italic> drug – receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder</article-title>] (in Japanese). <source>Jpn J Urol Surg</source> <volume>24</volume>: <fpage>915</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr47-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>S.</given-names></name>
<name><surname>Seki</surname><given-names>M.</given-names></name>
<name><surname>Ogoda</surname><given-names>M.</given-names></name>
<name><surname>Fukata</surname><given-names>A.</given-names></name>
<name><surname>Nakamura</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
</person-group> (<year>2011b</year>) <article-title>Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder</article-title>. <source>J Pharmacol Exp Ther</source> <volume>336</volume>: <fpage>365</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr48-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>O.</given-names></name>
<name><surname>Homma</surname><given-names>Y.</given-names></name>
</person-group> (<year>2009</year>) [<article-title>Long-term efficacy and safety of dose increase study of imidafenacin in patients with overactive bladder</article-title>]. <source>Jpn Pharmacol Ther</source> <volume>37</volume>: <fpage>909</fpage>–<lpage>930</lpage> (in Japanese).</citation>
</ref>
<ref id="bibr49-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamazaki</surname><given-names>T.</given-names></name>
<name><surname>Muraki</surname><given-names>Y.</given-names></name>
<name><surname>Anraku</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats</article-title>. <source>Naunyn-Schmiedebergs Arch Pharmacol</source> <volume>384</volume>: <fpage>319</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr50-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>A.</given-names></name>
<name><surname>Maruyama</surname><given-names>S.</given-names></name>
<name><surname>Fukumoto</surname><given-names>D.</given-names></name>
<name><surname>Tsukada</surname><given-names>H.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography</article-title>. <source>Life Sci</source> <volume>87</volume>: <fpage>175</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr51-1756287212459549">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaitsu</surname><given-names>M.</given-names></name>
<name><surname>Mikami</surname><given-names>K.</given-names></name>
<name><surname>Ishida</surname><given-names>N.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST Study)</article-title>. <source>Adv Urol.</source> doi:<pub-id pub-id-type="doi">10.1155/2011/854697</pub-id>.</citation>
</ref>
</ref-list>
</back>
</article>